TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04815200

Intervention type: DEVICE
Group type: OTHER
Intervention: Copper Nickel titanium arch wire
Description: Patient will receive 0.014 round Copper Nickel titanium CuNiTi archwire and will be ligated using a ligature wire.
Study: NCT06358716

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Complete Oral Nutrition Supplement 1
Description: Liquid formula produced by several food ingredients to provide a balance nutrient intake

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Complete Oral Nutrition Supplement 2
Description: Liquid formula produced by several food ingredients to provide a balance nutrient intake

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Complete Oral Nutrition Supplement 3
Description: Liquid formula produced by several food ingredients to provide a balance nutrient intake

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Complete Oral Nutrition Supplement 4
Description: Liquid formula produced by several food ingredients to provide a balance nutrient intake

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Complete Oral Nutrition Supplement 5
Description: Liquid formula produced by several food ingredients to provide a balance nutrient intake

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Complete Oral Nutrition Supplement 6
Description: Liquid formula produced by several food ingredients to provide a balance nutrient intake

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Complete Oral Nutrition Supplement 7
Description: Liquid formula produced by several food ingredients to provide a balance nutrient intake
Study: NCT05535101

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst transcranial magnetic stimulation (iTBS)
Description: The amphetamine users will undergo a one-month iTBS intervention. From Week 1 to Week 4, subjects will be treated five times a week.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham stimulation was delivered using the same protocol as active stimulation, but with the TMS coil rotated by 90 degrees with the edge of the coil touching the scalp.
Study: NCT06017648

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non Invasive Ultrasound (FUBA5200)
Description: the Focused Ultrasound Fat Reduction device (FUBA5200) is manufactured by Shanghai Carnation Medical Technology Co., Ltd

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non Invasive Ultrasound (Contour I V3)
Description: the Focused Ultrasound Fat Reduction device (Contour I V3) is manufactured by Syneron Medical Ltd.
Study: NCT05397743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life
Description: Questionnaire Perceived stress scale (PSS) + Questionnaire Short form 36 (SF-36) + Questionnaire Visual functioning questionnaire 25 (VFQ-25)
Study: NCT06383871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7058 capsule/ HRS-7058 tablet
Description: HRS-7058 capsule/ HRS-7058 tablet
Study: NCT05387174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: : Nursing intervention in two risk factors of the Metabolic Syndrome, abdominal obesity and arterial hypertension and quality of life in the climacteric period.
Description: Nursing intervention with technological support (Metamorphosis) in two risk factors of Metabolic Syndrome, abdominal obesity and hypertension and quality of life in the climacteric period, developed in 3 months, in the experimental group that includes individual nursing counseling, group education virtually and physical activity sessions for 12 weeks virtually.
Study: NCT05768126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine Transdermal Product
Description: The patches will be administered (first four weeks 4.6 mg and then 9.5. mg).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The sham patches will be administered during the same period of time as the rivastigmine.
Study: NCT05500716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular Non-Invazive Vagus Nerve Stimulation + Traditional Rehabilitation Program for TMD
Description: In this application, vagus nerve stimulation is applied to the patients in addition to the traditional rehabilitation program. In our research, vagal nerve stimulation will be applied with the Vagustim Device and all applications will be applied at a frequency of 10 Hz, a pulse amplitude of 300 microseconds and for 20 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Rehabilitation Program
Description: This intervention includes: Deep Friction Massage, Myofascial Trigger Point Compression Therapy, Temporomandibular Joint Mobilization, Rocabado Exercises, Muscle-Energy Techniques.
Study: NCT05502523

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Artery-First Surgical Technique
Description: Undergo pulmonary artery first surgical technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Correlative studies
Study: NCT04975074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron
Description: One of each type of iron was taken orally according to the instructions and followed every two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron
Description: One of each type of iron was taken orally according to the instructions and followed every two weeks
Study: NCT06358716

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Complete Oral Nutrition Supplement 8
Description: Liquid formula produced by several food ingredients to provide a balance nutrient intake

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Complete Oral Nutrition Supplement 9
Description: Liquid formula produced by several food ingredients to provide a balance nutrient intake

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 25 mg of glucose dissolved in 200 mL
Study: NCT05837234

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ULF SCS
Description: Ultra low frequency spinal cord stimulation
Study: NCT06613880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard IST combined with Romiplostim N01
Description: Romiplostim N01 is a class of TPO receptor agonists. Its TPO peptide can bind to TPO receptors on megakaryocyte precursors in the bone marrow and activate them, triggering a series of intracellular signalling pathways, including JAK2/STAT5, PI3K/Akt, MEK/ERK, and p38, which ultimately lead to gene transcription and increased megakaryocyte proliferation and differentiation.
Study: NCT05513859

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Craniotomy
Description: Undergo craniotomy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quantitative Oblique Back-Illumination Microscopy
Description: Undergo intraoperative microscopy utilizing qOBM
Study: NCT06434337

Intervention type: DIAGNOSTIC_TEST
Intervention: Novel point-of-care diagnostic test for detecting HPV (Rice HPV test)
Description: Given by Diagnostic Test
Study: NCT06671756

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose Ingestion
Description: Participants will consume a beverage containing 75g of fructose dissolved in 225ml of water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose Ingestion
Description: Participants will consume a beverage containing 75g of fructose dissolved in 225ml of water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose Ingestion
Description: Participants will consume a beverage containing 75g of glucose dissolved in 225ml of water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose Ingestion
Description: Participants will consume a beverage containing 75g of glucose dissolved in 225ml of water.
Study: NCT06621654

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine
Description: 1 dose (0.5ml) of vaccine on day 0, Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine
Description: 1 dose (0.5ml) of vaccine on day 0, Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Haemophilus Influenzae Type b Conjugate Vaccine
Description: 1 dose (0.5ml) of vaccine on day 0, Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine
Description: 3 doses (0.5ml per dose) at day 0, 1 month, and 18 months of age, Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Haemophilus Influenzae Type b Conjugate Vaccine
Description: 3 doses (0.5ml per dose) at day 0, 1 month, and 18 months of age, Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine
Description: 4 doses (0.5ml per dose) at day 0, 2, 4 month, and 18 months of age, Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Haemophilus Influenzae Type b Conjugate Vaccine
Description: 4 doses (0.5ml per dose) at day 0, 2, 4 month, and 18 months of age. Intramuscular injection
Study: NCT06685198

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Titrated administration of propofol to an OAA/S score of 1 as the endpoint
Description: Propofol is titrated at a rate of 0.5 mg/kg/min to achieve an OAA/S score of 1, followed by a maintenance dose of 2-4 mg/kg/h, concurrently with remifentanil 2 ug/kg and rocuronium 0.6 mg/kg for anesthesia induction.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Titrated administration of propofol to an OAA/S score of 2 as the endpoint
Description: Propofol is titrated at a rate of 0.5 mg/kg/min to achieve an OAA/S score of 2, followed by a maintenance dose of 2-4 mg/kg/h, concurrently with remifentanil 2 ug/kg and rocuronium 0.6 mg/kg for anesthesia induction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Titrated administration of propofol to a BIS value ≤ 60 as the endpoint
Description: Propofol is titrated at a rate of 0.5 mg/kg/min to achieve a BIS value ≤ 60, followed by a maintenance dose of 2-4 mg/kg/h, concurrently with remifentanil 2 ug/kg and rocuronium 0.6 mg/kg for anesthesia induction.
Study: NCT06698003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Description: Cohort 1: 0.3 mg/kg of mogamulizumab every 12 weeks, for 2 total doses Cohort 2: 0.3 mg/kg of mogamulizumab every 6 weeks, for 4 total doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Description: Cohort 1: 0.3 mg/kg of mogamulizumab every 12 weeks, for 2 total doses Cohort 2: 0.3 mg/kg of mogamulizumab every 6 weeks, for 4 total doses
Study: NCT06692894

Intervention type: OTHER
Intervention: Observational
Description: Blood will be collected from one cohort to identify potential blood biomarkers.
Study: NCT06715306

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral treatment
Description: Patients randomized to oral treatment will commence the oral treatment immediately. The oral treatment is based on specially developed treatment suggestions developed by microbiologists and specialists in infectious diseases from the participating regions, and in respect with local treatment guidelines (detailed described in the protocol).
Study: NCT06715800

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Honey
Description: Functional content analyses were performed to identify the specific properties of the different types of honey used.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Honey
Description: Functional content analyses were performed to identify the specific properties of the different types of honey used.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Honey
Description: Functional content analyses were performed to identify the specific properties of the different types of honey used.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Honey
Description: Functional content analyses were performed to identify the specific properties of the different types of honey used.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Honey
Description: Functional content analyses were performed to identify the specific properties of the different types of honey used.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Honey
Description: Functional content analyses were performed to identify the specific properties of the different types of honey used.
Study: NCT06716073

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: comparison of 2 surgical procedures
Study: NCT06718829

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stability Exercises
Description: Patients will perform core stability exercises three times weekly for eight weeks. The exercises include abdominal hollowing, bridge, right-angle leg lifts with thigh press, seated twist, knee-to-chest with elbow flexion, prone abdominal hollowing, prone arm and leg lift, quadruped abdominal hollowing, quadruped arm or arm-leg lifts, and various plank positions: forearm plank, side plank, forearm plank with hip raise, and forearm plank with straight legs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stability Exercises
Description: Patients will perform core stability exercises three times weekly for eight weeks. The exercises include abdominal hollowing, bridge, right-angle leg lifts with thigh press, seated twist, knee-to-chest with elbow flexion, prone abdominal hollowing, prone arm and leg lift, quadruped abdominal hollowing, quadruped arm or arm-leg lifts, and various plank positions: forearm plank, side plank, forearm plank with hip raise, and forearm plank with straight legs.
Study: NCT05980286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Piano Improvisation
Description: Piano Improvisation taught by a professional instructor for 16 weeks.
Study: NCT06718829

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensorimotor Training Exercises
Description: Patients will perform sensorimotor training exercises three times weekly for eight weeks, progressing through three phases: static (weeks 1-2), dynamic (weeks 3-4), and functional (weeks 5-8). Exercises, repeated 3-5 times per session with rest intervals, advance from simple to complex as patients master each level. Static exercises include standing on firm/soft surfaces and single-leg balances. Dynamic exercises add forward lunges and T-band kicks. Functional training incorporates walking on various surfaces, toe and heel skipping, squats, balance drills on wobble boards, and multidirectional rolling movements with visual and single-leg variations. This progression enhances coordination, balance, and functional stability.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensorimotor Training Exercises
Description: Patients will perform sensorimotor training exercises three times weekly for eight weeks, progressing through three phases: static (weeks 1-2), dynamic (weeks 3-4), and functional (weeks 5-8). Exercises, repeated 3-5 times per session with rest intervals, advance from simple to complex as patients master each level. Static exercises include standing on firm/soft surfaces and single-leg balances. Dynamic exercises add forward lunges and T-band kicks. Functional training incorporates walking on various surfaces, toe and heel skipping, squats, balance drills on wobble boards, and multidirectional rolling movements with visual and single-leg variations. This progression enhances coordination, balance, and functional stability.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy program
Description: All patients will undergo a traditional physical therapy program consisting of stretching exercises, strengthening exercises, and scar management techniques, three times weekly for eight weeks.
Study: NCT05980286

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music Listening
Description: Music Listening facilitated by a professional instructor for 16 weeks.
Study: NCT05814003

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxylate flavones solid dispersion application
Description: this drug has the antibacterial and anti inflammatory actions could help the palatal donor sites to promote the wound healing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxylate flavones solid dispersion application
Description: this drug has the antibacterial and anti inflammatory actions could help the palatal donor sites to promote the wound healing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hydroxylate flavones solid dispersion application
Description: this drug has the antibacterial and anti inflammatory actions could help the palatal donor sites to promote the wound healing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Dough inert material without any therapeutic action

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dough inert material without any therapeutic action
Study: NCT04893538

Intervention type: DIAGNOSTIC_TEST
Intervention: First analysis: Lymphocyte count > or = 1500 cells per microlitre, second analysis: IPS < 3 and third analysis: Lymphocyte/Monocyte ratio > or = 2.9
Description: Intravenous blood sampling from participants for complete blood count to obtain Lymphocyte count, Monocyte count and Lymphocyte/Monocyte Ratio and for plasma Albumin to obtain IPS

Intervention type: DIAGNOSTIC_TEST
Intervention: First analysis: Lymphocyte count < 1500 cells per microlitre, second analysis: IPS > or = 3 and third analysis: Lymphocyte/Monocyte ratio < 2.9
Description: Intravenous blood sampling from participants for complete blood count to obtain Lymphocyte count, Monocyte count and Lymphocyte/Monocyte Ratio and for plasma Albumin to obtain IPS
Study: NCT04797520

Intervention type: DEVICE
Group type: OTHER
Intervention: Eko CORE Stethoscope
Description: Eko CORE stethoscope will be used as a visual and auditory means of confirming placement of ETT

Intervention type: DEVICE
Group type: OTHER
Intervention: Point of care ultrasound
Description: Point of care ultrasound will be used as a means of confirming placement of ETT. This is the gold standard used in standard of care
Study: NCT05388240

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education via a Mobile App
Description: This group will have access to Education and Resources tab that includes customary information given at a pre-op appointment plus some additional related education and resources.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education and Exercise via a Mobile App
Description: This group will have access to Education and Resources tab that includes customary information given at a pre-op appointment plus some additional related education and resources. The app will also be used to help guide participants through an eight-week shoulder exercise program, together with physical therapy remote support.
Study: NCT04736043

Intervention type: OTHER
Intervention: Organoid
Description: The investigators create organoid from the pancreatic cancer tissue obtained via EUS-FNA and EUS-FNB within the pancreatic cancer diagnostic process. And also the investigators create organoid from the pancreatic cancer tissue obtained after surgery as part of the pancreatic cancer treatment process. Check for the reactivity to anti-cancer drugs through cell viability assay after treating with various anti-cancer drugs, such as anti-cancer drugs used as adjuvant chemotherapy for pancreatic cancer to the organoid. Also, perform genomic analysis on each organoid, and then check if there are any unique genomic mutations for each organoid. By recognizing the relationship between the unique genomic mutations and reactivity to the anti-cancer drug within pancreatic cancer patients eligible for surgery, the investigators aim to strategize appropriate adjuvant chemotherapy after surgery, thus developing a platform to predict the outcomes of each patient.
Study: NCT06051565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polysaccharide superparamagnetic iron oxide injection
Description: Polysaccharide superparamagnetic iron oxide injection can be used for the treatment of iron-deficiency anemia and for magnetic resonance imaging enhancement.
Study: NCT06428630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone oral rinse
Description: The study drug is FDA approved (NDC- 0054-3177) and will be used as it would be used in a standard of care setting. The rinse will be administered on the same therapeutic dose to OLP/OLR (0.5 mg/5ml of dexamethasone oral rinse once (rinse for 2 minutes or 5 minutes), then spit the excess into a cup.~The oral rinse dexamethasone 0.5 mg/5ml will be used only on the subjects who participated in the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone oral rinse
Description: The study drug is FDA approved (NDC- 0054-3177) and will be used as it would be used in a standard of care setting. The rinse will be administered on the same therapeutic dose to OLP/OLR (0.5 mg/5ml of dexamethasone oral rinse once (rinse for 2 minutes or 5 minutes), then spit the excess into a cup.~The oral rinse dexamethasone 0.5 mg/5ml will be used only on the subjects who participated in the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone oral rinse
Description: The study drug is FDA approved (NDC- 0054-3177) and will be used as it would be used in a standard of care setting. The rinse will be administered on the same therapeutic dose to OLP/OLR (0.5 mg/5ml of dexamethasone oral rinse once (rinse for 2 minutes or 5 minutes), then spit the excess into a cup.~The oral rinse dexamethasone 0.5 mg/5ml will be used only on the subjects who participated in the study.
Study: NCT05953766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: Presacral nerve block using 20mL of local ropivacaine 5.0mg/ml

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline injection
Description: Sham block using 20 mL of normal saline
Study: NCT05465460

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Banana Blossom
Description: Banana Blossom 225 mg tablet orally four times per day for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet orally four times per day for 14 days